| I-09 Jae Eun Ahn Longitudinal Model-Based Meta-Analysis for Liver Biomarkers and Biopsy Endpoints in Patients with Non-Alcoholic Fatty Liver Disease Wednesday 09:50-11:15 |
| I-44 Roberto Bizzotto Conditional linear mixed-effect modelling of HbA1c and fasting glucose in diabetic patients shows that progression rates for the two variables are different: an IMI DIRECT study Wednesday 09:50-11:15 |
| I-77 Valerie Cosson Target-mediated drug disposition model of RG6206 (RO7239361), an anti-myostatin adnectin-IgG1-Fc-fusion protein, with positive feedback on myostatin endogenous production in healthy adults but not in boys with Duchenne Muscular Dystrophy Wednesday 09:50-11:15 |
| II-04 Hanna Kunina Diabetes progression modelling of competing risks of long-term complications and mortality using Swedish registry data Wednesday 15:10-16:40 |
| II-37 Victor Mangas-Sanjuan Population Pharmacokinetic and exposure-efficacy Markov modelling of enzymatic activity in Gaucher disease patients treated with enzyme replacement therapy Wednesday 15:10-16:40 |
| II-55 Tadakatsu Nakamura A Model-Based Meta-Analysis (MBMA) of Efficacy of Different Drugs for Postmenopausal Vasomotor-Symptoms Wednesday 15:10-16:40 |
| II-70 Hyeonsoo Park A population pharmacokinetic model of Glimepiride(AmarylŪ) Wednesday 15:10-16:40 |
| II-75 Thomas Peyret Development of a Quantitative Systems Pharmacology Model to Support Dosing of rhPTH(1-84), a Recombinant Human Parathyroid Hormone, in Adult Patients with Hypoparathyroidism Wednesday 15:10-16:40 |
| III-02 Matthew Riggs M-EASE-1: A Modelling and simulation study conducted to further characterize the efficacy of low-dose Empagliflozin as Adjunctive to inSulin thErapy (M-EASE) in Type 1 Diabetes Mellitus Thursday 09:55-11:20 |
| III-10 Tomohisa Saito The evaluation of a population pharmacokinetic model of Tofogliflozin with the data from healthy volunteers and T2DM patients Thursday 09:55-11:20 |
| III-19 Iryna Sihinevich Mathematical Modeling of Glucose Homeostasis in Morbidly Obese Diabetic Patients Undergoing Roux-en-Y Gastric Bypass Surgery: An IMI DIRECT Study Thursday 09:55-11:20 |
| IV-01 Christiane Dings Mathematical modeling of the oral glucose tolerance test in pre-diabetic patients: An IMI DIRECT study Thursday 15:25-16:50 |
| IV-30 Anais Glatard Amisulpride: Real-World Evidence of Dose Adaptation and Effect on Prolactin levels using PK/PD modeling Thursday 15:25-16:50 |
| IV-66 Curtis Johnston M-EASE-2: A Modelling and simulation study conducted to further characterize the efficacy of low-dose Empagliflozin as Adjunctive to inSulin thErapy (M-EASE) in Type 1 Diabetes Mellitus (T1DM) Thursday 15:25-16:50 |
| IV-67 Daniel Jonker The impact of septic shock on the pharmacokinetics and pharmacodynamics of selepressin Thursday 15:25-16:50 |
| IV-81 Yun Kim A population pharmacokinetic/pharmacodynamic analysis of rosuvastatin according to OATP1B1 and BCRP polymorphisms in young and elderly subjects Thursday 15:25-16:50 |
